Inthelia - A Novel Method of Treating or Preventing Sepsis front page preview

Inthelia - A Novel Method of Treating or Preventing Sepsis

Sepsis is a major challenge in the intensive care unit, where it is one of the leading causes of death. It arises unpredictability and can progress rapidly. Cilengitide, a potent inhibitor prevents bacterial binding to ...

pdf 318.3KB

Novel Near Infra Red Dyes for the Endogenous Labelling of Exosomes front page preview

Novel Near Infra Red Dyes for the Endogenous Labelling of Exosomes

The recognition of the biological, diagnostic and medical importance of exosomes has given rise to an urgent need for efficient labelling of these extracellular vesicles in ways that do not alter their inherent character...

pdf 325KB

Novel RNA therapeutic targeting sodium channel genes for the treatment of  Genetic epilepsies front page preview

Novel RNA therapeutic targeting sodium channel genes for the treatment of Genetic epilepsies

Genetic epilepsies caused by mutations to voltage-gated sodium channels do not currently have adequate treatment options. These diseases begin in the early years of life, with infants suffering severe seizures as well as...

pdf 295.5KB

Rapid Acting Pharmaceutical for Infectious Disease (RAPID) front page preview

Rapid Acting Pharmaceutical for Infectious Disease (RAPID)

Sepsis is a major challenge in the intensive care unit, where it is one of the leading causes of death. It arises unpredictability and can progress rapidly. Cilengitide, a potent inhibitor prevents bacterial binding to ...

pdf 318.3KB

Highly Selective Inhibitors of HDAC6 for the Treatment of Cancers and Neurodegenerative Disease front page preview

Highly Selective Inhibitors of HDAC6 for the Treatment of Cancers and Neurodegenerative Disease

A novel structural class of highly-selective HDAC6 inhibitors. These patented small molecules have a unique non-hydroxamic acid chemical structure. The lead compound BAS-2 has been shown to inhibit glycolysis in triple ...

pdf 229.8KB